Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Pharmaceutical

Innate Pharma SA

Eric Vivier

Nicola Beltraminelli

Frederic Lombard

Odile Laurent

Yannis Morel

Odile Belzunce

Laure-Hélène Mercier

Henry Wheeler

Claire De Saint Blanquat

The Compliance and Legal team at Innate Pharma SA ensures adherence to regulatory standards and legal requirements throughout the drug development process. They oversee corporate governance, manage legal risks, support supply chain operations, and facilitate compliance with both national and international health regulations to uphold the integrity of the company’s biopharmaceutical innovations. Additionally, this team plays a critical role in safeguarding the company's interests during collaborations and partnerships in the healthcare industry.

Compliance and Legal

Advisory and Governance

Leadership Team

Compliance and Legal

About

Team members

Other teams at Innate Pharma SA

Advisory and Governance

Leadership Team